Propel Bio Management LLC Makes New $2.44 Million Investment in SAB Biotherapeutics, Inc. $SABS

Propel Bio Management LLC bought a new stake in SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 652,881 shares of the company’s stock, valued at approximately $2,442,000. SAB Biotherapeutics comprises about 2.1% of Propel Bio Management LLC’s investment portfolio, making the stock its 14th biggest position. Propel Bio Management LLC owned approximately 1.37% of SAB Biotherapeutics at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. ADAR1 Capital Management LLC bought a new position in shares of SAB Biotherapeutics in the 3rd quarter valued at about $30,000. Dimensional Fund Advisors LP acquired a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at approximately $32,000. State of Wyoming acquired a new stake in shares of SAB Biotherapeutics in the 4th quarter valued at approximately $34,000. Virtu Financial LLC acquired a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at approximately $40,000. Finally, Goldman Sachs Group Inc. raised its position in shares of SAB Biotherapeutics by 357.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 51,348 shares of the company’s stock valued at $192,000 after acquiring an additional 40,127 shares during the period. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Stock Performance

Shares of SABS stock opened at $3.38 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45. SAB Biotherapeutics, Inc. has a 52 week low of $1.60 and a 52 week high of $6.60. The company has a market capitalization of $258.43 million, a P/E ratio of -1.60 and a beta of 0.54. The company’s 50 day moving average price is $3.75 and its two-hundred day moving average price is $3.87.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). On average, analysts expect that SAB Biotherapeutics, Inc. will post -1.19 earnings per share for the current fiscal year.

Analyst Ratings Changes

SABS has been the topic of a number of analyst reports. Jefferies Financial Group initiated coverage on shares of SAB Biotherapeutics in a research report on Wednesday, May 20th. They issued a “buy” rating and a $11.00 price target on the stock. Zacks Research upgraded shares of SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Weiss Ratings reiterated a “sell (d+)” rating on shares of SAB Biotherapeutics in a research report on Friday, April 10th. HC Wainwright increased their price target on shares of SAB Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Finally, Wall Street Zen downgraded shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, SAB Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.